Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- NUVB
- Price
- 5.15
- Stock movement down
- -0.11 (-2.09%)
- Company name
- Nuvation Bio Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.76B
- Ent value
- 1.80B
- Price/Sales
- 653.37
- Price/Book
- 3.50
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 119.15%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-30
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NUVB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 653.37 |
| Price to Book | 3.50 |
| EV to Sales | 667.80 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 341.27M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 98.90M |
| Net receivables | 13.85M |
| Total current assets | 577.53M |
| Goodwill | 0.00 |
| Intangible assets | 11.68M |
| Property, plant and equipment | 0.00 |
| Total assets | 601.56M |
| Accounts payable | 15.36M |
| Short/Current long term debt | 10.46M |
| Total current liabilities | 68.13M |
| Total liabilities | 275.68M |
| Shareholder's equity | 0.00 |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 5.11 |
| Daily high | 5.40 |
| Daily low | 5.11 |
| Daily Volume | 11.4M |
| All-time high | 14.57 |
| 1y analyst estimate | 8.67 |
| Beta | 1.64 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| NUVB | S&P500 | |
| Current price drop from All-time high | -64.65% | -1.10% |
| Highest price drop | -88.61% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -82.42% | -2.76% |
| Avg time to new high | - | 5 days |
| Max time to new high | 266 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.76B
Marketcap category
Small-cap
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Employees
220
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page